Susac syndrome (SuS) is an orphan disease characterized by the triad of encephalopathy, branch retinal artery occlusions (BRAO), and sensorineural hearing loss. Onset occurs at mean age 31.6 and women are more often affected (3.5:1 female:male occurrence). Symptoms include episodes with headache, encephalopathic symptoms, focal neurologic deficits, sudden hearing loss for middle and low frequencies, and scintillating scotomata. Recent data show CD8+ T cells are involved in the autoimmune etiopathogenesis. Diagnosis is based on criteria that reflect the clinical and paraclinical fulfillment of the triad. Treatment consists of an empiric combination of immunosuppressants, monoclonal antibodies, intravenous immunoglobulins (IVIG), and plasma exchange.

Epidemiology, Etiology, and Pathophysiology

First described in 1979 by JO Susac,1 approximately 500 cases of SuS have since been reported, but incidence may be higher because of unreported or undiagnosed cases.2

Susac syndrome is an autoimmune disease of the small arterioles of the brain, retina, and inner ear that has been successfully treated with immunosuppressants, such as cyclophosphamide or steroids.3 Contrast enhancement of brain lesions and leptomeninges hints at an inflammatory process. Occlusions and hyperfluorescence of retinal arteries are signs of vasculitis. Cerebrospinal fluid (CSF) changes are typical for a sterile central nervous system (CNS) inflammation. Brain biopsies demonstrate microinfarcts with loss of neurons, axons, and myelin, and arterial vessel wall proliferation. CD8+-T–lymphocytic infiltrates and thickening of the basal membrane are seen.4-6 Similar changes have been described in muscle, gut and skin biopsies from people with SuS.7-9

A recent study elucidated SuS as a CD8+ T-cell–mediated endotheliopathy,10 in which circulating CD8+ T cells are clonally expanded and differentiate into activated granzyme B- and perforin-expressing cytotoxic CD8+ T cells. These cells accumulate in microvessels near endothelial cells, where they most likely cause injury. Elevated titers of antiendothelial cell antibodies were detected in 25% of people with SuS.11

Clinical Presentation and Course

Individuals with an encephalopathic course experience acute or subacute episodes of cognitive deficits, vigilance or mood changes, psychiatric symptoms (eg, psychosis or depression), fatigue, focal neurologic deficits, and, less frequently, seizures.2 Headaches often precede other symptoms by several months and are reported as being like tension-type or migraine headaches. Hearing loss can occur overnight, with a sudden loss of low, middle or all frequencies, and may be accompanied by an often roaring tinnitus.3,7 The BRAO can lead to scintillating or dark scotomata, or, because they are often located in the periphery of the retina, may be asymptomatic. In a systematic review, the classical clinical triad of symptoms was seen at disease onset in only 13% of cases.2

Because symptoms of the triad may appear successively with intervals up to several years, early diagnosis can be complicated. The mean number of relapses is 2.4, and the mean duration of active disease is 21 months, although some patients may have relapses for decades.12 The outcome depends on the residual symptoms after the episodes and may range from full recovery to severe disability. Cases of death have been described in individuals with SuS, but death is not caused by the disease but rather by treatment complications.13,14

Differential Diagnosis

The most important differential diagnosis is multiple sclerosis (MS), because age of onset, female preponderance, and callosal brain lesions occur in both diseases. It is also important to differentiate SuS from small vessel primary CNS vasculitis because corticosteroids should be tapered much more slowly in SuS than in CNS vasculitis. Other conditions in the differential diagnoses are psychosis, depression, infectious or autoimmune encephalitis, tumors, mild encephalopathy with reversible splenial lesions (MERS),15 stroke, mitochondrial diseases, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), and migraine.2 Ear and eye conditions in the differential include acute hearing loss; Menière syndrome; Cogan syndrome; retinal vasculitis; idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN) syndrome;16 retinal artery embolism; and vasospasm.15-17

Diagnosis

Magnetic Resonance Imaging

Brain MRI is crucial for diagnosis of SuS. Characteristic round snowball lesions in the center of the corpus callosum, are typical for the acute phase of SuS and can be seen best in fluid-attenuated inversion recovery (FLAIR) sequences (Figure 1).18,19 Of note and in contrast, MS lesions are typically located at the undersurface of the corpus callosum rather than in the center. Lesions of the white matter are frequently found in the centrum semiovale and in periventricular or subcortical regions, as well as in the cerebellum or the brainstem.18 Gray matter is affected in 70% of cases, and leptomeningeal contrast enhancement (30%) or contrast-enhancing lesions (70%) can be found in the acute disease phase.18 Diffusion restrictions in the acute phase represent ischemic strokes.20 Diffusion tensor imaging (DTI) demonstrates structural damages of the fiber integrity in the prefrontal cortex and the genu of the corpus callosum.21 On 7 T MRI, lesions in people with SuS are different from lesions of MS in that there is no central vein sign and rarely a hypointense rim.22

<p>Figure 1. Sagittal T2-weighted brain MRI in Susac syndrome demonstrating typical snowball lesions in the center of the corpus callosum. Neuroradiology, Alfried Krupp Hospital, Essen, Germany</p>

Click to view larger

Figure 1. Sagittal T2-weighted brain MRI in Susac syndrome demonstrating typical snowball lesions in the center of the corpus callosum. Neuroradiology, Alfried Krupp Hospital, Essen, Germany

Cerebrospinal Fluid Analysis

The CSF analysis findings in SuS also differ from those in MS, but resemble those seen in primary CNS vasculitis. In SuS, there are findings of mild lymphocytic pleocytosis, an elevation of the total protein up to 2 g/dL, and signs of a disruption of the blood CSF barrier are frequent and oligoclonal bands are not common.2,23,24 A recent study has shown that in contrast to MS no plasmacytoid cells occur in the CSF of SuS patients, whereas proportions of activated cytotoxic CD8 T cells are elevated.10

Ophthalmologic Diagnostics

Fluorescein angiography is the standard for detecting BRAOs and arterial wall hyperfluorescence in the acute phase of SuS (Figure 2). The detection of yellow mostly transient retinal arterial wall plaques or Gass plaques is considered pathognomonic.25,26 Optical coherence tomography (OCT) is a noninvasive technique to visualize postischemic retinal defects in the postacute phase that helps to differentiate SuS from MS.27

<p>Figure 2. Retinal fluorescein angiography of right eye of a person with Susac syndrome shows a branch retinal artery occlusion (arrow) and a hyperfluorescence (arrowhead) of a peripapillary nasal vessel. Department of Ophthalmology, University Hospital Bochum</p>

Click to view larger

Figure 2. Retinal fluorescein angiography of right eye of a person with Susac syndrome shows a branch retinal artery occlusion (arrow) and a hyperfluorescence (arrowhead) of a peripapillary nasal vessel. Department of Ophthalmology, University Hospital Bochum

Audiogram and Otologic Diagnostics

Because arteries feeding the apical cochlea are occluded,13 audiograms usually reflect nonspecific hearing loss, particularly in lower frequencies,5 that is often irreversible.23 Peripheral lesions of the vestibular organ can be detected by caloric testing of the vestibular organ, vestibular evoked myogenic potentials, or nystagmography.28

Diagnostic Criteria

To facilitate SuS diagnosis, diagnostic criteria have been suggested based on the characteristic clinical and paraclinical signs and symptoms of the triad, which are encephalopathy, hearing loss, and visual disturbances caused by BRAOs. In individuals who fulfill all 3 criteria, a definite diagnosis can be established. In cases with only 2 organs involved, the diagnosis should be considered as probable. There is no difference in treatment for probable vs definite SuS.28

Treatment

Because no randomized controlled trials of treatment of SuS have been done, there are no approved therapies. Treatment is empiric, consisting of immunotherapy combinations based on mostly retrospective case series and expert opinions. Some recommend an aggressive and early treatment and treat even mild courses with corticosteroids, IVIG, mycophenolate mofetil (MMF), and optionally, rituximab.29 Some> Others suggest corticosteroids and IVIG, adding rituximab and/or mycophenolate mofetil only in breakthrough disease, and cyclophosphamide, only if there is still disease activity after MMF and rituximab.30 Subcutaneous immunoglobulins have been successful and are well accepted by patients.31 In a retrospective case series, treatment with IVIG and plasma exchange was beneficial.24 Clinical stabilization has been reported after treatment with the tumor necrosis factor (TNF)-α inhibitors infliximab and adalimumab.6,32,33 Natalizumab resulted in a decrease of disease activity in 4 individuals.10 Antiplatelet therapy or anticoagulation effects are unknown, although we usually add an antiplatelet agent (eg, acetylsalicylic acid) owing to pathophysiologic considerations.34

Conclusion

In conclusion, SuS is a rare autoimmune disease with characteristic clinical and paraclinical features, which is important to differentiate from MS and other types of vasculitis. In clinical practice, for those with unclear encephalopathy, visual disturbances and sensorineural hearing loss, SuS has to be considered as a differential diagnosis, and cerebral MRI, fluorescein angiography, OCT, and audiogram should be performed.

Acknowledgements

This work was supported by German Research Foundation (DFG) grant GR3946_3/1 to CCG and IK and the Interdisciplinary Center for Clinical Studies (IZKF) grant Kl3/010/19 to CCG

1. Susac JO, Hardman JM, Selhorst JB. Microangiopathy of the brain and retina. Neurology. 1979;29(3):313-316.

2. Dorr J, Krautwald S, Wildemann B, et al. Characteristics of Susac syndrome: a review of all reported cases. Nat Rev Neurol. 2013;9(6):307-316.

3. Susac JO. Susac’s syndrome: the triad of microangiopathy of the brain and retina with hearing loss in young women. Neurology. 1994;44(4):591-593.

4. Petty GW, Engel AG, Younge BR, et al. Retinocochleocerebral vasculopathy. Medicine (Baltimore). 1998;77(1):12-40.

5. Susac JO, Egan RA, Rennebohm RM, Lubow M. Susac’s syndrome: 1975-2005 microangiopathy/autoimmune endotheliopathy. J Neurol Sci. 2007;257(1-2):270-272.

6. Hardy TA, O’Brien B, Gerbis N, et al. Brain histopathology in three cases of Susac’s syndrome: implications for lesion pathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2015;86(5):582-584.

7. O’Halloran HS, Pearson PA, Lee WB, Susac JO, Berger JR. Microangiopathy of the brain, retina, and cochlea (Susac syndrome). A report of five cases and a review of the literature. Ophthalmology. 1998;105(6):1038-1044.

8. Turc G, Monnet D, Dupin N, et al. Skin involvement in Susac’s syndrome. J Neurol Sci. 2011;305(1-2):152-155.

9. Marrodan M, Correale J, Alessandro L, et al. Gastrointestinal compromise in Susac Syndrome. J Neurol Sci. 2017;379:318-320.

10. Gross CC, Meyer C, Bhatia U, et al. CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome. Nat Comm.2019:published online first December 18, 2019.

11. Jarius S, Kleffner I, Dorr JM, et al. Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study. J Neuroinflammation. 2014;11:46.

12. Petty GW, Matteson EL, Younge BR, McDonald TJ, Wood CP. Recurrence of Susac syndrome (retinocochleocerebral vasculopathy) after remission of 18 years. Mayo Clinic Proc. 2001;76(9):958-960.

13. Francis HW, Makary C, Halpin C, Crane BT, Merchant SN. Temporal bone findings in a case of Susac’s syndrome. Otol Neurotol. 2011;32(8):1198-1204.

14. McLeod DS, Ying HS, McLeod CA, et al. Retinal and optic nerve head pathology in Susac’s syndrome. Ophthalmology. 2011;118(3):548-552.

15. Yuan J, Yang S, Wang S, Qin W, Yang L, Hu W. Mild encephalitis/encephalopathy with reversible splenial lesion (MERS) in adults-a case report and literature review. BMC Neurol. 2017;17(1):103.

16. Zacharia JA, Chin AT, Rebhun CB, et al. Idiopathic retinal vasculitis, aneurysms, and neuroretinitis syndrome presenting with branch retinal artery occlusion. Ophthalmic Surg Lasers Imaging Retina. 2017;48(11):948-951.

17. Dorr J, Jarius S, Wildemann B, et al. [Susac syndrome: an interdisciplinary challenge]. Nervenarzt. 2011;82(10):1250-1263.

18. Susac JO, Murtagh FR, Egan RA, et al. MRI findings in Susac’s syndrome. Neurology. 2003;61(12):1783-1787.

19. White ML, Zhang Y, Smoker WR. Evolution of lesions in Susac syndrome at serial MR imaging with diffusion-weighted imaging and apparent diffusion coefficient values. AJNR Am J Neuroradiol. 2004;25(5):706-713.

20. Xu MS, Tan CB, Umapathi T, Lim CC. Susac syndrome: serial diffusion-weighted MR imaging. Magn Reson Imaging. 2004;22(9):1295-1298.

21. Kleffner I, Deppe M, Mohammadi S, et al. Diffusion tensor imaging demonstrates fiber impairment in Susac syndrome. Neurology. 2008;70(19 Pt 2):1867-1869.

22. Wuerfel J, Sinnecker T, Ringelstein EB, et al. Lesion morphology at 7 Tesla MRI differentiates Susac syndrome from multiple sclerosis. Multiple Scler. 2012;18(11):1592-1599.

23. Aubart-Cohen F, Klein I, Alexandra JF, et al. Long-term outcome in Susac syndrome. Medicine (Baltimore). 2007;86(2):93-102.

24. Mateen FJ, Zubkov AY, Muralidharan R, et al. Susac syndrome: clinical characteristics and treatment in 29 new cases. Eur J Neurol. 2012;19(6):800-811.

25. Egan RA, Ha Nguyen T, Gass JD, Rizzo JF 3rd, Tivnan J, Susac JO. Retinal arterial wall plaques in Susac syndrome. Am J Ophthalmol. 2003;135(4):483-486.

26. Egan RA, Hills WL, Susac JO. Gass plaques and fluorescein leakage in Susac Syndrome. J Neurol Sci. 2010;299(1-2):97-100.

27. Ringelstein M, Albrecht P, Kleffner I, et al., Retinal Pathology in Susac Syndrome detected by spectral domain optical coherence tomography. Neurology. 2015;85(7):483-486.

28. Kleffner I, Dorr J, Ringelstein M, et al. Diagnostic criteria for Susac syndrome. J Neurol Neurosurg Psychiatry. 2016;87(12):1287-1295.

29. Rennebohm RM, Asdaghi N, Srivastava S, Gertner E. Guidelines for treatment of Susac syndrome - an update. Int J Stroke. 2018:1747493017751737.

30. Egan RA. Diagnostic criteria and treatment algorithm for Susac syndrome. J Neuroophthalmol. 2019;39(1):60-67.

31. Kleffner I, Dorr J, Duning T, Young P, Ringelstein EB, Schilling M. Susac syndrome treated with subcutaneous immunoglobulin. Eur Neurol. 2014;71(1-2):89-92.

32. Hardy TA, Garsia RJ, Halmagyi GM, et al. Tumour necrosis factor (TNF) inhibitor therapy in Susac’s syndrome. J Neurol Sci. 2011;302(1-2):126-128.

33. Buelens T, Ossewaarde-van Norel J, de Boer JH, et al. Evaluation of tumor necrosis factor inhibitor therapy in Susac syndrome. Retina. 2019. Published January 29, 2019. doi: 10.1097/IAE.0000000000002466. [Epub ahead of print]

34. Kleffner I, Ringelstein EB, Stupp N, Niederstadt TU, Young P. Neurological picture. Susac’s syndrome: effective combination of immunosuppression and antiplatelet treatment. J Neurol Neurosurg Psychiatry. 2006;77(12):1335.

IK has received travel grants from Pfizer and CSL Behring and speaker honoraria from Daiichi Sankyo.
CCG has received speaker honoraria and travel grants from Biogen, Euroimmun, Genzyme, MyLan, Novartis Pharma GmbH, and Bayer Health Care, none related to this study, and is funded by Biogen, Novartis, the German Ministry for Education and Research (BMBF; 01Gl1603A), the German Research Foundation (DFG, GR3946/3-1, SFB Transregio 128 A09), the European Union (Horizon2020, ReSToRE), and the Interdisciplinary Center for Clinical Studies (IZKF).
MR has received speaker honoraria from Novartis, Bayer, Roche and Ipsen and travel grants from Bayer Schering, Biogen, Merz, Genzyme, Teva, Grifols, Roche and Merck, none related to this study.
MK has received speaker honoraria from Roche Pharma and Chugai.
JD has received research support from Bayer and Novartis, travel grants from Bayer, Novartis, Biogen, Merck Serono, and honoraria for lectures and advisory by Bayer, Novartis, Biogen, Merck Serono, Roche, Sanofi Genzyme.